おかえりなさい
Click “ログイン” to agree to Cointime’s 利用規約 and acknowledge that Cointime’s プライバシーポリシー applies to you.
アカウント登録
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">利用規約</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">プライバシーポリシー</a> applies to you.
siteでログインする
siteで登録する
あなたのメールアドレス
受信トレイを確認する
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Regulus Therapeutics
company
About
Regulus Therapeutics is a clinical stage biopharmaceutical company focused on the development and discovery of microRNA therapeutics.
- 51 - 100
Highlights
Details
- Last Funding Type
- Funding Round
- Last Funding Money Raised
- $10M
- Industries
- Biotechnology,Genetics,Health Care,Therapeutics
- Founded date
- Sep 1, 2007
- Number Of Employee
- 51 - 100
- Operating Status
- Active
Regulus Therapeutics Is a biopharmaceutical company leading the discovery of a new class of high-impact medicines based on microRNAs. The discovery of MicroRNA in humans is one of the most exciting scientific breakthroughs in the last decade. MicroRNAs are small RNA molecules, typically 20 to 25 nucleotides in length, that do not encode proteins but instead regulate gene expression. It was founded in 2007 and is headquartered in Carlsbad, California.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$10M
Regulus Therapeutics has raised a total of
$10M
in funding over 2 rounds. Their latest funding was raised on
Oct 28, 2010 from a Funding Round round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Oct 28, 2010 | Funding Round | $10M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
Regulus Therapeutics is funded by 1 investors.
Sanofi
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Sanofi
|
— | Funding Round |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
